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Abstract
Background and Aims: Micro-RNAs (miRNAs) have recently emerged as crucial modulators of molecular processes involved
in chronic liver diseases. The few miRNAs with previously proposed roles in liver cirrhosis were identified in screening
approaches on liver parenchyma, mostly in rodent models. Therefore, in the present study we performed a systematic
screening approach in order to identify miRNAs with altered levels in the serum of patients with chronic liver disease and
liver cirrhosis.
Methods: We performed a systematic, array-based miRNA expression analysis on serum samples from patients with liver
cirrhosis. In functional experiments we evaluated the relationship between alterations of miRNA serum levels and their role
in distinct cellular compartments involved in hepatic cirrhosis.
Results: The array analysis and the subsequent confirmation by qPCR in a larger patient cohort identified significant
alterations in serum levels of miR-513-3p, miR-571 and miR-652, three previously uncharacterized miRNAs, in patients with
alcoholic or hepatitis C induced liver cirrhosis. Of these, miR-571 serum levels closely correlated with disease stages, thus
revealing potential as a novel biomarker for hepatic cirrhosis. Further analysis revealed that up-regulation of miR-571 in
serum reflected a concordant regulation in cirrhotic liver tissue. In isolated primary human liver cells, miR-571 was up-
regulated in human hepatocytes and hepatic stellate cells in response to the pro-fibrogenic cytokine TGF-b. In contrast,
alterations in serum levels of miR-652 were stage-independent, reflecting a concordant down-regulation of this miRNA in
circulating monocytes of patients with liver cirrhosis, which was inducible by proinflammatory stimuli like bacterial
lipopolysaccharide.
Conclusion: Alterations of miR571 and miR-652 serum levels in patients with chronic liver disease reflect their putative roles
in the mediation of fibrogenic and inflammatory processes in distinct cellular compartments involved in the pathogenesis of
liver cirrhosis.
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Introduction
Many chronic liver diseases are still not sufficiently treatable
and often progress to liver cirrhosis representing the major risk
factor for the development of hepatocellular carcinoma (HCC)
[1]. Despite recent advances e.g. in the treatment of viral
hepatitis, pharmacological strategies to prevent fibrogenesis, to
facilitate the reversal of fibrosis/cirrhosis or to prevent the
complications of advanced hepatic cirrhosis are still limited [2],
underlining the need to establish a better understanding of the
molecular mechanisms underlying the pathogenesis of hepatic
cirrhosis.
Micro-RNAs (miRNAs) are small, non-coding, 21–23 nucleo-
tide long RNAs that negatively regulate gene expression by base
pairing with the 39-untranslated region (UTR) of their target
mRNAs [3]. miRNAs are involved in highly regulated processes
such as cell injury, proliferation or carcinogenesis [4,5]. In the
liver, previous studies have shown that miRNAs play a
fundamental role in acute liver injury, viral hepatitis or
hepatocarcinogenesis [6,7,8,9]. In addition, systematic array
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cells (HSCs) recently revealed important functional roles of certain
miRNAs in hepatic fibrogenesis. As such, it was shown that
members of the miR-29 family integrate pro-fibrogenic and pro-
inflammatory signals in hepatic stellate cells and control expression
of various extracellular matrix genes during hepatic fibrogenesis
[10,11,12]. Since miRNAs control networks of target genes and
are thus promising therapeutic targets, such findings are of high
potential for the establishment of miRNA-based antifibrotic
therapies, which have already been tested in other organs like
the heart [13].
Previous studies on the role of miRNAs in chronic liver disease
have focused on certain miRNAs identified in screening
approaches on rodent liver samples or hepatic stellate cell cultures
[10,11,12,14]. However, some members of the broad spectrum of
human miRNAs are not yet established in rodent array systems.
Moreover, chronic liver disease and liver cirrhosis represent
systemic diseases with regulatory processes not only occurring in
the liver but also in other cellular compartments like immune cells
[15]. Therefore, alternative experimental approaches are needed,
which employ primary human specimen and acknowledge chronic
liver disease as a systemic disorder influenced by distinct cellular
compartments.
It has recently become evident that certain disease conditions are
associated with alterations in serum levels of miRNAs [16]. Despite
the potential of these findings for the establishment of novel
biomarkers, serum-level alterations of miRNAs might reflect
important regulatory processes occurring in distinct cellular
compartments involved in disease pathogenesis. In line with this
hypothesis, we recently demonstrated that the functional role of
miR-29 in liver fibrosis correlated with a significant decrease of
miR-29 serum levels [10]. Therefore, in the present study we
performed a comprehensive, unbiased array approach on serum
samples from patients and healthy controls in order to identify novel
miRNAs that play a role in chronic liver disease and liver cirrhosis.
Materials and Methods
Patients and controls
The study protocol was approved by the local ethics committee
(ethics committee of University Hospital Aachen, RWTH
Aachen), and written informed consent was obtained from each
patient. The study was conducted according to the principles
expressed in the Declaration of Helsinki.
We studied 67 patients with chronic liver diseases [15].
Characteristics of the study cohort are summarized in table 1.
Importantly, patients were excluded in case of systemic inflam-
matory response syndrome (SIRS) or sepsis, HIV-infection,
systemic steroid medication (prednisolone .7.5 mg/d or equiva-
lent doses) and malignant tumor(s) except for hepatocellular
carcinoma. As a control group, 17 matched healthy volunteers
were recruited from the local blood transfusion institute that had
normal aminotransferase activities, no history of liver disease or
alcohol abuse and were tested negative for HBV, HCV and HIV
infections.
All blood samples were taken by one physician, and strictly the
same protocol was applied to all samples (centrifugation time,
materials, etc.). Furthermore a ‘‘needle to freezer time’’ of less than
30 min was defined for all samples. All samples were handled at
4uC until storing them for final analysis at 280uC. RNA
extraction and cDNA transcription was performed simultaneously
for all samples.
For tissue-specific miRNA-regulation analysis, samples were
taken from explanted cirrhotic livers (n=13) from patients that
underwent liver transplantation with different disease etiologies
(Data S1) [15]. As controls, liver tissues were obtained from
patients undergoing partial liver resection for hepatic metastases of
colorectal cancer. Only liver tissues judged as non-cancerous by
local pathologists and without histological evidence for both liver
fibrosis and inflammation were used to serve as control tissue [15].
miRNA isolation from serum
Total RNA, including miRNA, was extracted from serum
samples using Phenol-Chloroform extraction as previously de-
scribed [10,11,12]. In short, 400 ml serum was spiked with 20 nM
miScript miRNA mimic SV40 (Qiagen) for sample normalization
according to references [6,17,18,19,20] (Figure S1). 800 ml Phenol
(Qiazol, Qiagen, Hilden; Germany) and 200 ml Chloroform were
added to the sample and mixed vigorously for 15 sec followed by
incubation at room temperature for 10 min. Samples were
centrifuged for 15 min at 12,000 g until complete phase
separation. The aqueous phase, containing total RNA, was
Table 1. Clinical data of patients with liver cirrhosis.
Child-Pugh stages of liver cirrhosis
Controls All patients no cirrhosis Child A Child B Child C
[n(%)] 17 67 6 (9%) 25 (37.3%) 10 (14.9%) 26 (38.8%)
Gender (m/f) [n(%)] 12/5 43/24 2/4 16/9 6/4 19/7
Age (years) 46 (23–68) 58 (29–82) 39 (29–56) 62 (37–82) 57 (40–77) 55 (38–81)
Etiology [n(%)]
Viral Hepatitis 18 (26.9%) 2 (33.3%) 9 (36%) 5 (50%) 2 (7.7%)
Biliary 5 (7.5%) 0 (0%) 2 (8%) 2 (20%) 1 (3.8%)
Alcohol 43 (64.2%) 4 (66.7%) 13 (52%) 3 (30%) 23 (88.5%)
Cryptogenic 1 (1.5%) 0 (0%) 1 (4%) 0 (0%) 0 (0%)
Complications [n(%)]
Ascites 28 (41.8%) 1 (1.6%) 4 (16%) 6 (60%) 17 (65.4%)
Esophageal varices 35 (52.2%) 0 (0%) 10 (40%) 6 (60%) 19 (73.1%)
Encephalopathy 10 (14.9%) 0 (0%) 0 (0%) 1 (10%) 9 (34.6%)
doi:10.1371/journal.pone.0032999.t001
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(Fermentas, St. Leonroth; Germany) over night at 220uC. After
centrifugation at 4uC for 15 min (12,000 g) the pellets were
washed once with 70% ethanol. Precipitated RNA was resus-
pended in 30 ml RNase free water (Ambion, Austin, TX). To
assess the quantity and quality of RNA, the samples were
measured using a NanoDrop spectrophotometer (NanoDrop,
Wilmington, DE) and by microfluidic electrophoresis using a
Small RNA Chip for Agilent’s Bioanalyzer (Agilent Technologies,
Waldbronn).
Microarray
Total RNA was extracted as described above. For cDNA
synthesis, 1,5 ng of total RNA was transcribed in a 10-mL volume
with the TaqMan microRNA RT kit (Applied Biosystems, Foster
City, CA) according to the manufacturer’s recommendations.
Because of generally low RNA concentrations in serum, an
additional pre-amplification step for miRNAs was performed using
the MegaPlex RT & PreAmp Human Pool Set (Applied
Biosystems). 2,5 ml cDNA was used for the pre-amplification
reaction and the pre-amplification product was diluted for further
analysis according to the manufacturer’s recommendations. For
the miRNA screening, quantitative real-time PCR was performed
with the TaqMan human miRNA array pool A and B v2.0
(Applied Biosystems). 9 mL of the diluted pre-amplification
product was used in each of the real-time PCR arrays. P-value
adjustment was performed using the Bejamini-Hochberg method.
All analysis have been performed MIAME-compliant and raw
data were deposited in a MIAME- compliant database (ArrayEx-
press), as detailed on the MGED Society website http://www.
mged.org/Workgroups/MIAME/miame.html. The accession
number will be received during the review.
Isolation of HSC and hepatocytes from human livers
Primary human HSC were isolated from tissue samples
obtained from patients undergoing partial liver resection.
Experimental procedures were performed according to guidelines
of the local ethics committee with patient’s informed consent.
Primary HSC were isolated using EGTA/collagenase perfusion
and pronase incubation, and seperation from nonparenchymal
liver cells was attained by arabinogalactan gradient ultracentrifu-
gation as described previously [17]. HSC were cultured in
Dulbecco’s modified Eagle’s medium supplemented with 10%
fetal calf serum and 100 U/ml penicillin/streptomycin. Stimula-
tion of the HSC was carried out on 6-well-plates with 10 ng/mL
recombinant human TGF-b1 (R&D Systems) and as control, cells
were left untreated.
Primary human hepatocytes were isolated and cultivated in
serum-free medium (DMEM supplemented with 4.5 g/l glucose,
0.4 ng/ml hydrocortisone, 0.415 mU/ml insulin, 2 mM gluta-
mine, and 100 U/ml penicillin/streptomycin) as previously
described [21].
Isolation of monocytes and lymphocytes from human
blood
Blood of healthy donors was collected in EDTA tubes and
directly applied to PBMC isolation by Ficoll Density Gradient
(LSM-1077, PAA) and further CD14
+CD16
2 and CD14
+CD16
+
monocytes were selectively purified by MACS methodology using
‘Monocyte-isolation-Kit-II’ and ‘CD16
+-monocytes-isolation-kit’,
respectively (Miltenyi). Lymphocytes serving as control cells were
isolated from PBMC after depletion of monocytes with anti-CD14
microbeads.
For further materials and methods please see Data S1.
Results
Systematic profiling of serum miRNA levels in patients
with distinct entities of liver cirrhosis
We performed a systematic array analysis on miRNA-serum
levels of patients with liver cirrhosis from different entities and
compared them to expression profiles of healthy controls (Figure 1
A). The screening cohort consisted of four age- and sex-matched
patients with histologically and clinically confirmed compensated
alcoholic liver cirrhosis (Child-Pugh class A), four patients with
decompensated alcoholic cirrhosis (Child-Pugh class C), four
patients with compensated hepatitis C-related cirrhosis (Child-
Pugh class A) and four healthy volunteers as controls (Data S1).
While several miRNAs with high-fold-changes were detected, only
three of the individual miRNAs represented on the microarray
showed significantly diverging levels between healthy controls and
liver cirrhosis patients. Of these three miRNAs, levels of miR-513-
3p and miR-571 were significantly increased while levels of miR-
652 were significantly decreased (Figure 1 A). Array results for
these latter three as well as three other representative miRNAs
(miR-10a, mir-29a and miR-221) were confirmed by qPCR
(Figure S2 A, B). Furthermore, a hierarchical cluster analysis for
miR-513-3p, miR-571 and miR-652 revealed two distinct subsets,
one containing the control samples and the other containing all
cirrhosis patients included into the array analysis (Figure 1 B), thus
confirming the different abundance between patients and controls.
Apart from these three significantly regulated miRNAs, we
identified a panel of miRNAs with divergent pattern between
patients and controls in our array analysis, of which a striking
number had been previously studied in the context of liver disease
and organ fibrosis, including miR-99 (up) [22], miR-30e (down)
[23], miR-132 (up) [24], miR-196b (down) [25] and miR-221 (up)
[26] (Figure 1 A). However, only miR-513-3p, miR-571 and miR-
652 reached statistical significance (Figure 1 B). Thus, by applying
a systematic array approach, we identified a subset of miRNAs
differentially regulated in sera of patients with liver cirrhosis of
hepatitis C and alcoholic etiology.
Next, we analyzed serum levels of miR-513-3p, miR-571 and
miR-652 in a cohort of 17 healthy controls and 67 patients with
chronic liver diseases by qPCR analysis (Table 1). In this larger
collective, we observed a significant alteration for miR-513-3p,
miR-571 and miR-652 in patients with liver cirrhosis, which was
concordant to the previous findings in the array analysis (Figure 2
A). In addition, three other miRNAs (miR-10a, miR-29a, miR-
221), which were strongly but not significantly altered or unaltered
in the array, showed a concordant and significant regulation in the
larger collective (Figure S2 C). Of note these results could be
confirmed in a second, independent collective of patients with liver
cirrhosis that were compared with a collective of patients treated
for non-hepatic diseases (Figure S3). Moreover, we validated our
results by analyzing serum levels of certain miRNAs that were
previously shown to be altered in cirrhotics (miR-21, miR-34a,
miR-122) [17,27,28]. In line with these previous findings, qPCR
analysis revealed an up-regulation of miR-34a and miR-122 in our
larger qPCR-cohort, while levels of miR-21 were unchanged
(Figure S4).
Finally, ROC curve analysis showed that miR-513-3p, miR-571
and miR-652 were highly predictive for the presence of liver
disease/cirrhosis (Figure 2 B). Their diagnostic accuracy could
even be increased, when miRNA serum levels were combined
(Figure 2 C) and were dramatically superior to that of classical
markers such as platelets, INR or albumin (AUROC about 0.6),
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results in a large cohort of liver disease patients by qPCR indicated
an involvement of miR-513-3p, miR-571 and miR-652 in the
pathogenesis of liver cirrhosis.
Association of miRNA-serum-patterns with etiology and
stage of cirrhosis
We next analyzed our array data with respect to miRNA
regulations in serum between either different stages of liver
cirrhosis or different etiologies in order to identify more specific
stage- or etiology-dependent miRNAs, with a focus on the
regulation of miR-652, miR-571 and miR-513-3p. By using
hierarchical cluster analysis of all miRNAs comparing Child A and
C cirrhosis due to alcoholic disease, the samples split into two
defined clusters, differentiating patients with compensated from
patients with decompensated cirrhosis (Figure 3 A). However,
when we tried to define specific single miRNAs distinguishing
early and late stages of cirrhosis, only miR-140 and miR-340 were
significantly regulated on the array level between both groups
(Figure 3 B). The subsequent qPCR analysis from the total cohort
of patients confirmed a trend for a differential regulation of miR-
140 and miR-340, but did not reach statistical significance (Figure
S5). On the other hand, among the previously identified miR-652,
miR-571 and miR-513-3p, only serum levels of miR-571 were
significantly elevated in patients with Child C compared to Child
A cirrhosis (Figure 3 C). Interestingly, serum levels of miR-571
were significantly correlated with biomarkers of liver synthesis
capacity such as pseudocholinesterase (PCHE), prothrombin time,
international normalized ratio (INR) or coagulation factor V
activity (Data S1), raising the possibility that this distinct miRNAs
could serve as a novel serum biomarker reflecting disease severity
in liver cirrhosis.
To evaluate if serum miRNA patterns are also dysregulated in
an etiology-specific way we next compared serum miRNA
expression patterns between patients with alcoholic and hepatitis
C cirrhosis at the same stage of liver disease (Child-Pugh class A).
Figure 1. Systematic profiling of serum miRNA levels in patients with distinct entities of liver cirrhosis. (A) Microarray analysis for
miRNA levels was performed using RNA extracts from serum of four healthy subjects as control and patients with liver cirrhosis of different etiologies
and stages of disease (for detailed clinical parameters see Data S1). The fifteen miRNAs with strongest up- or down-regulation are depicted.
Significantly regulated miRNAs are highlighted in bold type. (B) Hierarchical cluster analysis of the significantly regulated miRNAs miR-513-3p; miR-
571; miR-652; bright green: under-expression; black: no change; bright red: over-expression.
doi:10.1371/journal.pone.0032999.g001
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distinct clustering between alcoholic and hepatitis C cirrhosis
(Figure 3 D). Seven miRNAs in the array analysis collective were
regulated significantly different between these two groups (Figure 3
E), but significance was lost when the larger cohort was analyzed
by qPCR. Importantly, miR-652, miR-571 and miR-513-3p did
not differ dependent on disease etiology (Figure 3 F). Furthermore,
to exclude a bias in regulation of these miRNA by co-morbidities
or demographic differences, we correlated miR-652, miR-571 and
miR-513-3p levels with age, gender, body mass index and serum
creatinine concentration. None of these single parameters
correlated with these miRNAs (Data S1). Therefore, in line with
our initial hypothesis, the gene array approach indeed allowed us
to identify three etiology-independent miRNAs specifically
regulated in serum of liver disease patients, with miR-571 being
a previously unrecognized miRNA that is also closely associated
with the stage of liver cirrhosis.
Serum levels of miR-571 and miR-652 reflect their specific
regulation in distinct cellular compartments involved in
the pathogenesis of liver cirrhosis
It is presently unclear and controversially debated which
molecular mechanisms are responsible for alterations in serum
miRNA levels in certain disease conditions. Especially, it is not
known if changes in serum levels reflect a passive release of
miRNAs during cell death or if they are actively secreted and
might play a functional role as ‘‘messengers’’ [29,30]. We thus
aimed at assessing if divergent patterns of the identified set of
serum miRNAs correlated with their regulation in the cellular
compartments that are most likely involved in the initiation and
Figure 2. Serum levels of miR-513-3p, miR-571 and miR-652 are significantly altered in the serum of patients with chronic liver
disease and liver cirrhosis. (A) Serum levels of the three significantly regulated miRNAs (miR-513-3p; miR-571; miR-652) were analyzed by qPCR in
a collective of 17 healthy controls and 67 patients with chronic liver disease and liver cirrhosis. Results are depicted as box plot. The thick line
represents the median of relative expression. (B) Receiver operating characteristic (ROC) curve analysis displaying the diagnostic power in predicting
cirrhosis of these miRNAs when analyzed as single markers (area under the curve (AUC) 0.87; 0.91; 0.75). (C) ROC curve analysis displaying the
diagnostic power in predicting cirrhosis of different combinations of these miRNAs (AUC 0.91; 0.962; 0.9676). **P,0.001.
doi:10.1371/journal.pone.0032999.g002
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circulating immune cells such as monocytes or lymphocytes
[15,31].
To test the hypothesis that these miRNAs are differentially
regulated within distinct compartments, we analyzed primary
human liver tissue from cirrhotic patients (Data S1) and also
isolated primary circulating monocytes as well as lymphocytes
from patients with liver cirrhosis and healthy controls at high
purities using magnetic bead separation techniques (Data S1).
Interestingly, only levels of miR-571, but not of miR-652 or miR-
513-3p, were concordantly regulated between serum and liver
tissue from cirrhosis patients compared to healthy controls
(Figure 4 A), suggesting that the liver is the primary source of
serum miR-571 in cirrhosis patients. In contrast and concordant
with its serum-specific regulation, miR-652 was significantly down-
regulated in circulating monocytes isolated from patients com-
pared to controls (Figure 4 B), while none of the three miRNAs
were significantly dysregulated in the lymphocyte compartment
(Figure 4 C).
In order to elucidate which hepatic cell population involved in
liver cirrhosis likely contributes to miR-571 regulation in liver and
serum of cirrhotic patients, we compared cell type-specific
expression levels of these miRNAs in isolated primary human
hepatocytes, hepatic stellate cells and monocytes/macrophages
(Figure 4 D). Interestingly, miR-571 was expressed at similar levels
in all of these cell compartments. In contrast, expression of miR-
652 was restricted to monocytes/macrophages, indicating primary
functions in regulating innate immune responses. Altogether, these
data indicate that alterations of serum levels of miR-571 and miR-
652 in liver cirrhosis patients reflect distinct regulatory mecha-
nisms in different cell compartments involved in this disease,
namely the liver and monocytes.
Figure 3. Correlation of miRNA serum levels with Child-Pugh class and etiology of liver disease. (A) Microarray data of the serum of eight
patients with alcoholic liver cirrhosis at different stages of disease (Child-Pugh A and Child-Pugh C) in a hierarchical cluster analysis; bright green:
under-expression; black: no change; bright red: over-expression. (B) Hierarchical cluster analysis of the significantly regulated miRNAs; bright green:
under-expression; black: no change; bright red: over-expression. (C) Serum levels of miR-513-3p, miR-571 and miR-652 in the patients with alcoholic
liver cirrhosis were analyzed by qPCR. Results are depicted as box plot. The thick line represents median of relative expression. (D) Microarray data of
serum of the serum of four patients with ethanol-toxic liver cirrhosis (Child-Pugh A) and the four hepatitis C related cirrhosis (Child-Pugh A) in a
hierarchical-cluster-analysis; bright green: under-expression; black: no change; bright red: over-expression. (E) Hierarchical cluster analysis of the
significantly regulated miRNAs; bright green: under-expression; black: no change; bright red: over-expression. (F) Serum levels of miR-513-3p, miR-571
and miR-652 in the patients with alcoholic liver cirrhosis (Child-Pugh A) and hepatitis C related cirrhosis (Child-Pugh A) were analyzed by qPCR.
Results are depicted as box plot. The thick line represents median of relative expression. **P,0.01.
doi:10.1371/journal.pone.0032999.g003
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inflammatory signals in human HSCs and monocytes
Based on the prominent up-regulation of hepatic and circulating
miR-571 in cirrhotic patients, we hypothesized that miR-571
might be centrally involved in cellular responses to profibrogenic
signals. The most relevant collagen-producing cell types in liver
fibrosis are HSCs, and the cytokine TGF-b is one of the key
profibrogenic mediators [32,33]. When primary human HSCs,
isolated from cirrhotic liver explants, were stimulated with TGF-b,
miR-571 was significantly up-regulated (Figure 5 A). On the other
hand, miR-652 did not show a specific regulation upon TGF-b
stimulation. However, stimulation of monocytic U937 cells with
the proinflammatory ligand bacterial lipopolysaccharide (LPS) led
to a significant down-regulation of miR-652, while miR-571
remained unaffected (Figure 5 B). These data support that miR-
571 is involved in the regulation of hepatic fibrogenesis, while
Figure 4. Serum levels of miR-571 and miR-652 reflect their specific regulation in distinct organs and cell compartments involved in
the pathogenesis of liver cirrhosis. (A) Expression of miR-513-3p, miR-571 and miR-652 was analyzed by qPCR in liver samples of patients with
liver cirrhosis (n=13) and livers from patients without chronic liver disease (n=10) as control. (B) Expression of miR-513-3p, miR-571 and miR-652 was
analyzed by qPCR in MACS-sorted monocytes of patients with liver cirrhosis (n=19) and healthy donors (n=19) as control. (C) Expression of miR-513-
3p, miR-571 and miR-652 was analyzed by qPCR in lymphocytes of patients with liver cirrhosis (n=11) and healthy donors (n=6) as control. Results
are depicted as dot plot with each dot representing one individual patient. The line represents the mean of relative expression. (D) qPCR analysis of
miR-571 and miR-652 expression in human primary hepatocytes, HSCs and monocytes, respectively. Results are depicted as mean, error bars denote
SEM. *P,0.05, ***P,0.001.
doi:10.1371/journal.pone.0032999.g004
Figure 5. miR-571 and miR-652 integrate pro-fibrotic and inflammatory signals in human HSCs and monocytes. (A) Expression of miR-
571 and miR-652 in primary human HSCs in response to stimulation with TGF-b for 48 h was measured by qPCR. Results are depicted as dot plot with
each dot representing one individual patient. The line represents the mean of relative expression. (B) We stimulated U937 cells with PMA into a
monocytic differentiation. miR-571 and miR-652 expression levels in response to stimulation with LPS for 48 h were measured by qPCR. Results are
depicted as dot plot with each dot representing one individual patient. The line represents the mean of relative expression. (C) Expression of CREBBP
was analyzed by qPCR in liver samples of patients with liver cirrhosis (n=13) and non-liver diseased donors (n=10) as control. Results are depicted as
mean, error bars denote SEM. (D) HuH-7 cells and LX-2 cells were transfected with indicated amounts of miR-571 mimic. Expression of CREBBP was
determined after two days of transfection by qPCR. Results are depicted as mean, error bars denote SEM. (E) Activation of stellate cells was
determined by qPCR-based analysis of SMA- and Col1A1-expression in LX-2 cells. **P,0.01, ***P,0.001.
doi:10.1371/journal.pone.0032999.g005
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nying the pathophysiological processes during liver cirrhosis in
monocytes/macrophages.
To our knowledge, there is currently no published information
on possible functions and putative target genes of these respective
miRNAs available. To get a first insight into their function, we
performed a broad in silico- target screen for putative miR-571
targets, the miRNA with the most prominent regulation in our
analysis, by using two different miRNA-target prediction algo-
rithms. Among others, we identified CREB-binding protein
(CREBBP) as a possible target gene for miR-571 (Data S1), a
gene involved in general transcriptional regulation previously
associated with the regulation and pathogenesis of liver fibrosis
[34,35]. In line with up-regulation of miR-571, CREBBP was
down-regulated in liver tissue from cirrhosis patients compared
with healthy controls (Figure 5 C). Moreover, transfection of
HuH-7 and LX-2 cells, cell lines representing human hepatocytes
or HSC, respectively, with miR-571 led to a moderate, but
significant down-regulation of CREBBP on RNA level (Figure 5
D), suggesting that CREBBP might be one possible target gene
mediating miR-571-dependent effects in the regulation of liver
cirrhosis. Finally, up-regulation of miR-571 leads to a moderate
up-regulation of SMA and Col1A1 in LX-2 cells, indicating that
miR-571 might be involved in activation of stellate cells during
fibrogenesis (Figure 5 E).
Discussion
While previous screening approaches to study the role of
miRNAs in liver fibrosis/cirrhosis focused on their regulation in
liver tissue or hepatic stellate cells [10,11,12], in the present study
we performed a systematic array approach on serum samples from
liver cirrhosis patients. By this approach, we identified a set of
three miRNAs, miR-513-3p, miR-571 and miR-652, which to our
knowledge have previously not been characterized in liver cirrhosis
nor in any other physiological or pathological condition in humans
or rodents. The key prerequisite for their identification was the
significant alteration in serum even in the relatively small collective
of samples included in the array analysis, which was then
confirmed within the larger cohort of chronic liver disease
patients. To our opinion, this approach thus represents a successful
methodological alternative to previous studies, which mainly
addressed regulations of pre-defined, single miRNAs in serum
[10]. Moreover, our array approach included patients with
alcoholic and hepatitis C-related liver disease, enabling us to
identify miRNAs with putative etiology-independent roles in
hepatic cirrhosis. From these three miRNAs, miR-571 not only
identified most reliably patients with chronic liver diseases, but was
also closely associated with cirrhosis progression, underlining its
potential as a novel serum biomarker. Therefore, further
evaluation in larger prospective trials is warranted to assess its
potential diagnostic or prognostic value in patients with hepatic
fibrosis or cirrhosis.
Serum parameters in general can show certain variability, and
the reproducibility of serum tests depends on the nature of the
marker itself as well as the standardized handling and preparation
of the sample. While protein based markers are more or less prone
to degradation [20], it has been consistently shown that serum
miRNAs remain stable after being subjected to severe conditions
that would normally degrade most RNAs, such as boiling, very low
or high pH levels, extended storage, and 10 freeze–thaw cycles
[36]. Moreover, specimen collection, processing, and purification
of miRNA were strictly standardized in the present study in order
to avoid any bias (see Materials and Methods). In line with
numerous previously published studies [6,17,19,20], we used
spiked-in RNAs that were added into the serum sample before
miRNA extraction for normalization of miRNA serum levels. This
method is preferred by many groups to other normalization
methods. As such, it was suggested that frequently used reference
genes like U6 small nuclear RNA (RNU6B) and 5S ribosomal
RNA show a less stable expression than others and are easily
degraded in serum samples [37,38]. Furthermore, levels of certain
miRNAs (miR-142-3p and miR-16) that were claimed to be evenly
expressed in patient and control serum samples in some studies
were found to be significantly altered in others [17,39]. The fact
that by using spiked-in RNA for normalization we could show a
similar regulation of certain miRNAs (miR-21, miR-34a, miR-
122) [17,27,28] as demonstrated previously in other cohorts of
cirrhotics (Figure S4) as well as our confirmatory experiments in a
second, independent cohort of liver cirrhosis patients (Figure S4)
strongly support the robustness of the de-regulation of the newly
identified miRNAs in chronic liver disease.
The key finding of this study was a striking concordance
between miRNA-levels in the serum and their specific regulations
in different cellular compartments involved in the pathogenesis of
chronic liver disease, raising the yet unanswered question which
molecular processes underlie regulation of miRNA serum levels
and if serum-miRNAs might withhold a specific function. On one
hand, increased levels of miRNAs such as miR-513-3p or miR-571
might reflect an epiphenomenon resulting from increased hepatic
cell death in chronic liver disease, a hypothesis that cannot be
ruled out on basis of our data. However, some recent data have
provided evidence that some miRNAs are not only passively
released but in turn actively secreted from cells and integrated into
vesicles, potentially serving as messengers to influence gene
transcription in other cells [29,30]. The specific up-regulation of
miR-571 in HSC, the main matrix-producing cell compartment
activated during fibrogenesis, in response to TGF-b, the most
prominent pro-fibrogenic cytokine [32], supports a contribution of
these cells to changes in miR-571 serum levels. Given the vast
amount of potential miR-571-target genes, among those
CREBBP, a general modulator of gene transcription [40], it is
conceivable that miR-571 is released from certain hepatic cells in
an active process to modulate transcriptional programs in other
cells or cell compartments involved in liver cirrhosis. Interestingly,
we previously demonstrated a similarly concordant regulation
between liver tissue and serum levels in liver cirrhosis for miR-29
[10]. In contrast, miR-221, which is up-regulated in livers of
cirrhosis patients [26], showed a down-regulation in the serum in
our array analysis (see Figure 1 A), which was confirmed as
significant by qPCR in our large collective (Figure S2). These data
suggest that different molecular processes are connecting serum
levels of distinct miRNA with their tissue-specific regulation in the
liver. However, the quantitative relations between alterations in
intracellular miRNA concentrations and serum miRNA levels are
not known.
miR-652 represented another strongly regulated miRNA in
patients with chronic liver disease, on which further experiments
revealed interesting differences to miR-571. Most strikingly, miR-
652 showed a significant down-regulation in patients with chronic
liver disease, correlating with its regulation in circulating
monocytes rather than parenchymal or resident liver cells. The
selective expression of miR-652 in innate immune cells supports
the hypothesis that indeed this cellular down-regulation played a
causative role for decreased serum levels in the patient group. The
finding that miR-652 levels integrated proinflammatory stimuli
like LPS suggests that this miRNA is involved in the mediation of
inflammatory signals in immune cells. These mechanisms are
Serum miRNAs Patterns in Human Liver Cirrhosis
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immune response mechanism present in many chronic inflamma-
tory conditions such as hepatic fibrosis. In line with this hypothesis,
miR-652 showed a high predictive value for the presence of
chronic liver disease but did not correlate with the stage of
cirrhosis. Therefore, next to further functional characterizations in
monocytes/macrophages, it might be interesting to test serum
levels and the predictive value of miR-652 in other acute and
chronic inflammatory disease states, e.g. rheumatoid arthritis,
inflammatory bowel disease or sepsis.
In conclusion, using a systematic array approach on serum
samples from patients with chronic liver disease, we identified
etiology-independent alterations of serum levels of miR-513-3p,
miR-571 and miR-652, three previously uncharacterized miR-
NAs. Moreover, we demonstrated that miR571- and miR-652-
serum levels in patients with chronic liver disease reflect their
putative roles in the mediation of fibrogenic and inflammatory
processes in distinct cellular compartments involved in the
pathogenesis of liver cirrhosis. These results might lead to the
identification of novel regulatory networks in different cellular
compartments as a basis for future miRNA-based therapeutic
strategies for the treatment of chronic liver disease and liver
cirrhosis.
Supporting Information
Data S1 Overview of supplementary data and supple-
mentary tables.
(DOC)
Figure S1 SV40 and U6 were used for normalization of
PCR based analysis. (A) SV40 levels, used for normalization in
further experiments, were determined by qPCR in sera of patients
with liver cirrhosis and controls. (B) U6 expression, used for
normalization in further experiments, were determined by qPCR
in livers samples of patients with liver cirrhosis and controls.
(TIF)
Figure S2 Confirmation of the array based results by
using qPCR. (A) Levels of miR-513-3p, miR-571 and miR-652
were analyzed by qPCR in the samples used for the initial array
analysis in order to confirm the array based results. (B) miR-29a,
miR-221 and miR-10a were analyzed by qPCR in the samples
used for the initial array analysis in order to further confirm the
array based results by extending this analysis on other miRNAs.
(C) Serum levels of miR-29a, miR-221 and miR-10a were
analyzed in the large collective of patients with liver cirrhosis
and controls, revealing comparable results to the analysis in the
smaller collective used for array analysis. *P,0.05, ***P,0.001.
(TIF)
Figure S3 Confirmation of alterations of serum levels of
miR-513-3p, miR-571 and miR-652 in a second cohort of
patients. Serum level of miR-513-3p, miR-571 and miR-652
were analyzed in a second collective of patients with chronic liver
disease and patients without chronic liver disease (n=13 each) in
order to confirm that the alterations remain stable when patients
instead of healthy individuals were used as control. *P,0.05.
(TIF)
Figure S4 Validation of the array- and qPCR based
data. (A) Microarray analysis for miRNA levels was performed
using RNA extracts from serum of four healthy subjects as control
and patients with liver cirrhosis of different etiologies and stages of
disease (for detailed clinical parameters see Data S1). Three
miRNAs previously published in the context of liver cirrhosis are
depicted to confirm the reliability of the array based results. (B)
Serum levels of miR-21, miR-34a and miR-122 were analyzed in
the large collective of patients with liver cirrhosis and controls,
revealing comparable alterations to previously published results.
**P,0.01, ***P,0.001.
(TIF)
Figure S5 Analysis of miR-140 and miR-340 in the
serum of patients with liver cirrhosis. (A) Serum levels of
miR-140 and miR-340 in the patients with alcoholic liver cirrhosis
(Child-Pugh A and Child-Pugh C) were analyzed by qPCR.
Results are depicted as box plot. The thick line represents median
of relative expression. (B) ROC curve analysis displaying the
diagnostic power of selected miRNAs in predicting advanced stage
of liver cirrhosis.
(TIF)
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